The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback